Little Green Pharma Continues Record Breaking Sales Growth
April 2020 – a record sales month with 1,850+ units sold, a 17% increase on March 2020 (previous record sales month)
380 new patients prescribed LGP products in April (for a cumulative total of over 3,550 patients) and 28 new prescribersThe Office of Drug Control continues review of LGP’s application for an expanded Cultivation Permit and has granted an extension to LGP’s existing permit in the interimMONTRÉAL, May 28, 2020 (GLOBE NEWSWIRE) — Elixxer Ltd. (TSX-V: ELXR) (OTC-QB: ELIXF) (FRA: 2LQA) (“ELIXXER” or (the “Company”) Pharmaceutical medical cannabis partner, Little Green Pharma (ASX:LGP) of Australia, has provided a sales update for the month of April 2020.LGP has achieved another record-breaking month in April 2020, with:Sales of 1,850+ units of LGP Classic product (a new monthly record), a 17% increase on March 2020 sales;380 New patients being prescribed LGP medicinal cannabis products (a cumulative total of 3,550+ patients have been prescribed LGP medicinal cannabis products as at 30 April 2020); and28 New healthcare professionals prescribed LGP’s products (for a total of 272 healthcare professionals prescribing LGP products).Commenting on the record monthly sales, Little Green Pharma Managing Director Fleta Solomon, said:“Little Green Pharma’s continued growth trajectory in sales and patients is indicative of our determination to achieve our goal of delivering high quality and affordable medicinal cannabis products to our patients both domestically and globally. It is a testament to our hard work and further highlights the strong demand for our world-class suite of medicinal cannabis oil products.”About Elixxer Ltd. (www.Elixxer.com)ELXR Ltd. is a Canadian public company listed on the TSX Venture Exchange (TSX-V: ELXR), the US OTC-QB exchange (OTCQB: ELIXF) and the Frankfurt Exchange (FRA: 2LQA).Through its partners ELXR presently has significant interests in Australia, Jamaica, Switzerland, Italy and Canada.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For further information please contact:President, John McMullen, +1-416-803-0698, [email protected]Caution Regarding Press ReleasesNeither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Notice Regarding Forward Looking StatementsThis press release may contain forward-looking statements with respect to Elixxer and its operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Elixxer, including completion of the Loan and any future investment or acquisition, could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in Elixxer’s most recent Management’s Discussion and Analysis filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to Elixxer and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and Elixxer has no obligation to update such statements, except to the extent required by applicable securities laws.